Healthcare

November 18, 2019

1

Interim analysis from EMPRISE real-world study shows empagliflozin decreased risk of hospitalisation for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists

A new interim analysis of three-year data from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) real-world study on effectiveness shows that empagliflozin was associated with a decreased risk of hospitalisation for heart failure and a similar risk of non-fatal atherosclerotic cardiovascular events compared with DPP-4 inhibitors and GLP-1 receptor agonists.1 The interim analysis included 190,000 adults in the US with type 2 diabetes with and without cardiovascular disease. The results were shared today on behalf"...

Continue Reading >

November 16, 2019

2

Under the patronage and in the presence of H.E. Sheikh Dr. Saeed bin Tahnoun Al Nahyan unveils 17th clinic of CosmeSurge

H.E. Sheikh Dr Saeed bin Tahnoun Al Nahyan, inaugurated CosmeSurge’s 17th clinic. With clinics across UAE and Oman, CosmeSurge is one of the region’s most trusted brands for cosmetic and aesthetic procedures. The new clinic opened in Zakher, Al Ain, will offer unique and specialist treatments that will redefine your beauty.

NMC Healthcare's Director of Corporate Operations Strategy Clancey Po launched the latest facility, which will"...

Continue Reading >

November 14, 2019

3

Takeda Announces 12 New Molecular Entities with the Potential for 14 Launches in the Next Five Years at 2019 R&D Day

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) will host an R&D meeting today beginning at 12:30 p.m. EST in New York City to outline how its science-first, patient-centric strategy, diverse portfolio of approved medicines and its R&D engine is expected to drive the company’s near-term and sustained growth. In the near-term, Takeda expects that its 14 current global growth brands will generate significant momentum enabled by at least 20 additional indications and major market expansions through FY24. In the same time period, the organization anticipates delivering 12 new molecular entities with the potential for 14 launches, representing best-in-class or first-in-class therapies across its core areas of focus. Looking ahead to FY25 and beyond, Takeda’s transformative R&D engine comprising internal research capabilities and external......

Continue Reading >

November 12, 2019

4

Mamador Targets School Children through Campaign

In a bid to promote and encourage healthy feeding habits among Nigerians, premium brand, Mamador, has launched a campaign spurring Nigerians to adopt a healthy and balanced breakfast lifestyle.

The campaign seeks to emphasise the importance of breakfast as the most important meal of the day as well as provide information on easy and affordable breakfast options and recipes.

According"...

Continue Reading >

November 12, 2019

5

Boehringer Ingelheim and Lilly initiate first ever study to assess empagliflozin in people hospitalised for acute heart failure who have been stabilised

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced the initiation of EMPULSE, the sixth Phase III study in the empagliflozin heart failure programme. The study will assess whether in-hospital administration of empagliflozin 10 mg daily improves heart failure outcomes when initiated in people hospitalised for any type of acute heart failure event once they have been stabilised. The study will include participants both with and without type 2 diabetes.

This"...

Continue Reading >

November 11, 2019

6

Mary Kay Continues Its Commitment to Advance Skin Science Research at the Japanese Society of Investigative Dermatology

As a leader in skincare innovation worldwide, Mary Kay Inc. continued its commitment to advance skin science as a symposium sponsor at the 44th annual meeting of The Japanese Society of Investigative Dermatology (JSID). At the conference held Nov. 8 - 10 in Aomori, Japan, the symposium on skin barriers and skin redness provided a collaborative environment to share technological advances and breakthroughs on skin health.

Established in 1981, the"...

Continue Reading >

November 11, 2019

7

Male infertility is becoming a growing concern for couples looking to start a family

To raise awareness regarding matters surrounding men’s health and in observance of ‘Movember,’ an annual event involving the growing of moustaches all through the month of November, Fakih IVF Fertility Center has a special line-up of services rolled out for all its male patients.

As part of the services, all male patients will be provided with a free semen analysis, with an additional 15 percent discount on all IVF-ICSI packages."...

Continue Reading >

November 10, 2019

8

Phase 3 Trial of NINLAROTM (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell Transplantation

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) (Takeda) today announced the randomized, Phase 3 TOURMALINE-MM4 study met its primary endpoint of progression free survival (PFS). The trial evaluated the effect of single-agent oral NINLARO™ (ixazomib) as a first line maintenance therapy versus placebo in adult patients diagnosed with multiple myeloma not treated with stem cell transplantation. TOURMALINE-MM4 is the first industry sponsored Phase 3 trial to explore the concept of “switch” maintenance, the use of medicines not included in initial induction therapy, in this setting. NINLARO is currently not approved for this specific use. “We are very encouraged by the results of the TOURMALINE-MM4 trial and continue our forward momentum in developing maintenance options for multiple myeloma patients. Importantly, this is the third positive Phase 3 readout......

Continue Reading >

November 8, 2019

9

New Analyses from the Phase 3 HELP Study™ Open-Label Extension in Hereditary Angioedema Evaluate Efficacy and Safety of TAKHZYRO® (lanadelumab-flyo) Injection During Extended Study Treatment Period

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced new data that further investigates the long-term safety and efficacy of TAKHZYRO® (lanadelumab-flyo) injection in patients with hereditary angioedema (HAE) 12 years of age and older studied in the ongoing Phase 3 HELP (Hereditary Angioedema Long-term Prophylaxis) Study™ Open-label Extension (OLE). The analyses, being presented at the 2019 American College of Allergy, Asthma and Immunology (ACAAI) Annual Meeting in Houston, Texas from November 7-11, showed that TAKHZYRO continued to prevent HAE attacks at a rate similar to that observed in the pivotal HELP Study, in patients who received treatment for a mean duration of 19.7 (0-26.1) months.1, 2 The analyses will also be published in the November issue of ACAAI’s journal Annals of Allergy, Asthma & Immunology. The original Phase......

Continue Reading >

November 7, 2019

10

Takeda’s Dengue Vaccine Candidate Demonstrates Protection in Children Ages Four to 16 Years, Regardless of Previous Dengue Exposure

− New England Journal of Medicine publishes primary endpoint analysis from ongoing Phase 3 study of Takeda’s dengue vaccine candidate

− Over 20,000 study participants in dengue-endemic areas in Latin America and Asia received two doses of Takeda’s dengue vaccine candidate or placebo administered three months apart

− Results demonstrated overall vaccine efficacy of 80.2% (12-month follow-up after second dose) against virologically confirmed dengue; exploratory analyses"...

Continue Reading >


Forex News Headline



Forex Market Video